Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|January 1, 2006
- Volume 0 0
Hydase (hyaluronidase injection, USP)
Advertisement
PrimaPharm Inc (San Diego, Calif) recently received FDA approval for a new drug application for Hydase 150 units/mL for use as a spreading agent to facilitate the dispersion and absorption of other drugs. Hydase is also indicated for hypodermoclysis and as an adjunct in the subcutaneous urography for improving resorption of radiopaque agents. The product is supplied sterile as 150 USP units of hyaluronidase per mL in a 2-mL nonpreserved, single-use glass vial. For more information, call 866-339-6589, or visit
Articles in this issue
over 20 years ago
Resealable and Nultraviolet Ultraviolet (UV) Inhibitant Bagsover 20 years ago
High Alert Insulin Binover 20 years ago
Humira (adalimumab)over 20 years ago
INVANZ (ertapenem for injection)over 20 years ago
Compounding HOTLINEover 20 years ago
Customer Guilty of Prescription Fraud by Supporting Friendover 20 years ago
Counterfeit Drugs: A Life-or-Death Problemover 20 years ago
Qui Tam Lawsuits Blow the Whistle on PBMsover 20 years ago
Can You Read These Rxs?over 20 years ago
What You Need to Know About Alzheimer's DiseaseAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
3
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
4
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
5